omniture
logo
Search
礼邦医药
Media Room

Latest News

rss

Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "...

2026-05-06 12:00 3062

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of h...

2026-03-17 20:00 6335

Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffecti...

2025-11-07 20:00 2150
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund...

2025-06-26 20:00 2436

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals

2025-01-07 21:00 2826

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebun...

2024-03-29 20:00 2973

Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund...

2023-12-13 21:00 2661